<DOC>
	<DOCNO>NCT02751385</DOCNO>
	<brief_summary>Investigate effect multiple oral dos nintedanib single dose kinetics combination ethinylestradiol levonorgestrel ( Microgynon® )</brief_summary>
	<brief_title>Investigation Effect Nintedanib Pharmacokinetics Combination Ethinylestradiol Levonorgestrel Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Inclusion criterion : Female patient 18 year old screen Female patient postmenopausal surgically sterilise Patient locally advance , metastatic locally recurrent nonsmall cell lung cancer histology adenocarcinoma Nintedanib ( Vargatef® ) plan prescribed accordance marketing authorisation ( SmPC ) Signed date write informed consent accordance Good Clinical Practice ( GCP ) local legislation prior admission trial Exclusion criterion : Any contraindication nintedanib ( Vargatef® ) , ethinylestradiol levonorgestrel ( Microgynon® ) , specify respective label Use hormone contain contraceptive ( include vaginal intrauterine device include hormone replacement therapy ) within 30 day prior first administration Microgynon® Systemic use drug know induce ( e.g . rifampicin , St. John 's Wort , carbamazepine ) inhibit ( e.g . azole antimycotic , macrolides ) CYP3A4 within 7 day prior first trial drug administration last PKsampling trial . Exception : allow intake corticosteroid docetaxel ( pre ) medication History major thrombotic clinically relevant major bleed event past 6 month Persistence clinically relevant therapy relate toxicity ( i.e . &gt; Common Terminology Criteria Adverse Events [ CTCAE ] grade 2 ) previous chemotherapy and/or radiotherapy Treatment investigational drug treatment another clinical trial within past four week start therapy concomitantly trial Gastrointestinal disorder abnormality would interfere absorption trial drug Major surgery ( major accord investigator 's assessment ) perform within 4 week prior first treatment within trial without complete wound heal Patients must wish continue intake restricted medication drug consider likely interfere safe conduct trial Patients unable comply protocol Previous enrolment trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>